Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... , September 23, 2014 ... from Imperial Innovations, Cambridge Innovation Capital and Johnson ... clinical cancer genomics company focused on harnessing the ... improve cancer testing and treatment, today announced it ... by Imperial Innovations and including Cambridge Innovation Capital ...
    (Date:9/22/2014)... YORK and SANTA CLARA, Calif. ... Corp. (NASDAQ: WBMD ), the leading source ... new WebMD/Medscape survey that provide novel insights ... in aiding diagnosis and care.  Dr. Eric Topol ... and digital medicine, who serves as both Editor-in-Chief of ...
    (Date:9/22/2014)... fragments whose job it is to stop bleeding, are ... they can "feel" the physical environment around them, researchers ... respond to surfaces with greater stiffness by increasing their ... platelets and other components of the clotting system, the ... them credit for, in that they are able to ...
    (Date:9/22/2014)... University of Minnesota electrical engineering researchers have developed ... time demonstrates mechanical transportation of light. The discovery ... more efficient optical devices for computation and communication. ... electrical and computer engineering assistant professor Mo Li ... published online and will appear in the October ...
    Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2Engineers show light can play seesaw at the nanoscale 2
    ... April 20 Shire plc (LSE: SHP,NASDAQ: SHPGY ), the global ... , , Results press release will be issued at: ... Investor conference call time: ... EDT, , Live conference call for investors: , ...
    ... Mass. April 20 Advanced Instruments, ... Multi-Sample Osmometer as the first true automation-friendly osmometer ... Multi-Sample Osmometer is specifically designed for ... osmolality testing in the biopharmaceutical laboratory," said Kelly ...
    ... Inc., a development-stage pharmaceutical company discovering and developing ... James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, ... at this year,s American Society for Pharmacology and ... place from April 18-22, 2009 in New Orleans. ...
    Cached Biology Technology:Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 3
    (Date:9/23/2014)... EdmontonCleaning up oil sands tailings has just gotten a ... University of Alberta civil engineering professors that uses solar ... , Instead of using UV lamps as a light ... retained in tailings ponds, professors Mohamed Gamal El-Din and ... a renewable energy source treats the wastewater just as ...
    (Date:9/23/2014)... more carbon than the atmosphere and small changes ... effect on atmospheric greenhouse gas concentrations. A new ... concludes that climate warming does not accelerate ... storage, despite increases in ecosystem productivity. , ... Ecologist Dr. Christian Giardina, with the agency,s Institute ...
    (Date:9/23/2014)... West Orange, NJ. September 23, 2014. Kessler Foundation ... of a foot drop stimulator during a task-specific ... system. This finding indicates that applying the foot ... from this common complication of stroke. "EMG of ... utilization of a foot drop stimulator," was published ...
    Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2Study helps assess impact of temperature on belowground soil decomposition 2
    ... Consumers shouldn,t assume that, because a product is ... University of Guelph study reveals some organic pesticides ... pesticides because the organic product may require larger ... PhD candidate Christine Bahlai compared the effectiveness and ...
    ... that governs flower formation has been uncovered in the daisy-like ... BMC Plant Biology have published a pair of articles ... this process differs from other model plants, such as the ... Teeri, from the University of Helsinki, Finland, worked with a ...
    ... been puzzled by the ability of microscopic algae to grow ... essential algal nutrient. In this week,s issue of Nature, ... Riser at the University of Washington and David Karl at ... from deep water, as much as 250 meters below the ...
    Cached Biology News:Organic pesticides not always 'greener' choice, study finds 2Researchers discover source of essential nutrients for mid-ocean algae 2Researchers discover source of essential nutrients for mid-ocean algae 3
    ... clone d1-174 GenBank Accession Number : ... N-terminal tagged fusion protein corresponding to full ... Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium ... 30% Quality Assurance: routinely evaluated by immunoblot ...
    Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
    Recombinant Rat Fas Ligand/TNFSF6...
    FGF Receptor 1 Antibody...
    Biology Products: